

Drug Use Result Survey of Botox Vista® Injection 50 Units

First published: 08/11/2016

Last updated: 20/02/2024

Study

Ongoing

Administrative details

EU PAS number

EUPAS16104

Study ID

30867

DARWIN EU® study

No

Study countries

☐ Japan

Study description

Objective The purpose of this survey is to collect and evaluate the information on the safety, efficacy and proper use of Botox Vista® Injection 50 Units (hereinafter referred to as “Botox”) in adult patients less than 65 years, who

undergo the treatment of expression lines of lateral canthus (crow's feet lines) during actual use. Inclusion Criteria1) Patients who undergo the treatment with Botox for the first time (initial administration group) or2) Patients with an experience of the treatment with Botox (repeated administration group)3) Less than 65 years at the time of treatmentSample Size1080 patientsFollow-up PeriodAll patients shall be followed up from time of study drug injection to 6 months after study drug administration Total Survey Period2 years and 6 months after product launch Survey Items to be Collecteda) Information on Institutionb) Identifying Information on Patientc) Patient Background Informationd) Prior Treatment History for Facial Wrinkles e) Information on Current Botox Administrationf) Information on Efficacy Evaluation (this includes evaluation of degree of wrinkle improvement by patient and physician, patient satisfaction with treatment)g) Use of Commitment Drug h) Information on Antibody Examination for Botulinum Toxin Type Aii) Presence or Absence of AEsj) Type of AEK) Evaluation of AE Relationship to Study DrugL) Exposure to Study Drug During Pregnancy

Study status

Ongoing

Research institutions and networks

Institutions

Quintiles

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Anita Verga CT.Disclosures@abbvie.com

Study contact

CT.Disclosures@abbvie.com

Primary lead investigator

Anita Verga

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 14/06/2016

Study start date

Planned: 28/12/2016

Actual: 21/12/2016

Date of final study report

Planned: 22/08/2020

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Allergan

Study protocol

[\(Japan\) Botox in CFL E-DUI_protocol_20160316 \(2\).pdf](#) (150.89 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Drug utilisation

Effectiveness study (incl. comparative)

Main study objective:

To collect and evaluate information on the safety, effectiveness and use of Botox Vista injection in adult patients younger than 65 years of age who are administered the study drug for the treatment of cross's feet lines.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine, other

Botox Vista Injection 50 units

Study drug International non-proprietary name (INN) or common name

BOTULINUM TOXIN TYPE A

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Estimated number of subjects

1080

Study design details

Data analysis plan

Purely descriptive analysis.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No